Y-mAbs Therapeutics Quarterly Balance Sheets Chart
Quarterly
|
Annual
Y-mAbs Therapeutics Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | ||||||||||||||||||||||||||||
| current assets | ||||||||||||||||||||||||||||
| cash and cash equivalents | 62,293,000 | 60,310,000 | 67,234,000 | 68,122,000 | 77,806,000 | 75,749,000 | 78,637,000 | 86,571,000 | 87,909,000 | 92,629,000 | 105,762,000 | 114,526,000 | 133,665,000 | 156,724,000 | 181,564,000 | 215,730,000 | 233,587,000 | 252,271,000 | 114,634,000 | 131,267,000 | 158,059,000 | 185,774,000 | 207,136,000 | 98,192,000 | 120,163,000 | 134,245,000 | 147,840,000 | 163,292,000 |
| accounts receivable | 15,740,000 | 17,740,000 | 19,688,000 | 19,916,000 | 22,191,000 | 20,588,000 | 22,454,000 | 18,874,000 | 19,118,000 | 18,702,000 | 12,531,000 | 9,251,000 | 7,208,000 | 9,324,000 | 7,712,000 | 7,264,000 | 8,517,000 | 5,997,000 | ||||||||||
| inventories | 9,719,000 | 7,995,000 | 7,214,000 | 9,557,000 | 8,498,000 | 8,448,000 | 5,065,000 | 7,113,000 | 5,187,000 | 8,945,000 | 6,702,000 | 6,242,000 | 6,794,000 | 5,588,000 | 5,512,000 | 4,787,000 | 3,820,000 | 1,005,000 | ||||||||||
| other current assets | 4,035,000 | 4,403,000 | 4,373,000 | 1,462,000 | 2,243,000 | 3,482,000 | 4,955,000 | 2,302,000 | 3,570,000 | 3,730,000 | 5,452,000 | 3,225,000 | 6,253,000 | 6,103,000 | 7,473,000 | 2,799,000 | 3,445,000 | 4,736,000 | 7,729,000 | 1,942,000 | 5,261,000 | 4,062,000 | 1,399,000 | 3,027,000 | 2,759,000 | 3,661,000 | 2,721,000 | |
| total current assets | 91,787,000 | 90,448,000 | 98,509,000 | 99,057,000 | 126,763,000 | 108,267,000 | 111,111,000 | 114,860,000 | 115,784,000 | 124,006,000 | 130,447,000 | 133,244,000 | 153,920,000 | 177,739,000 | 202,261,000 | 230,580,000 | 249,369,000 | 264,009,000 | 122,363,000 | 133,209,000 | 163,320,000 | 189,836,000 | 99,591,000 | 123,190,000 | 137,034,000 | 151,532,000 | 166,044,000 | |
| property and equipment | 269,000 | 161,000 | 42,000 | 53,000 | 87,000 | 153,000 | 224,000 | 296,000 | 375,000 | 511,000 | 604,000 | 1,372,000 | 1,554,000 | 1,697,000 | 1,847,000 | 1,846,000 | 1,919,000 | 2,095,000 | 1,825,000 | 1,888,000 | 1,894,000 | 1,992,000 | 1,689,000 | 390,000 | 400,000 | 205,000 | 162,000 | |
| operating lease right-of-use assets | 3,109,000 | 601,000 | 817,000 | 1,075,000 | 1,271,000 | 1,179,000 | 1,412,000 | 1,593,000 | 1,178,000 | 1,369,000 | 1,739,000 | 2,169,000 | 2,381,000 | 3,155,000 | 3,842,000 | 2,802,000 | 3,398,000 | 3,979,000 | 4,569,000 | 5,123,000 | 1,758,000 | 1,865,000 | 2,086,000 | 2,216,000 | 2,320,000 | |||
| intangible assets | 2,177,000 | 2,213,000 | 2,276,000 | 2,366,000 | 2,454,000 | 2,543,000 | 2,631,000 | 2,720,000 | 2,809,000 | 2,898,000 | 2,986,000 | 1,530,000 | 1,574,000 | 1,618,000 | 1,663,000 | |||||||||||||
| inventories, long-term | 19,223,000 | 18,472,000 | 17,772,000 | |||||||||||||||||||||||||
| other assets | 646,000 | 718,000 | 488,000 | 18,366,000 | 13,460,000 | 11,173,000 | 12,491,000 | 9,415,000 | 12,250,000 | 8,661,000 | 5,680,000 | 5,600,000 | 5,749,000 | 6,838,000 | 3,170,000 | 4,751,000 | 4,793,000 | 4,833,000 | 3,290,000 | 2,975,000 | 357,000 | 381,000 | 318,000 | 244,000 | 243,000 | 187,000 | 188,000 | |
| total assets | 117,211,000 | 112,613,000 | 119,904,000 | 120,917,000 | 144,035,000 | 123,315,000 | 127,869,000 | 128,884,000 | 132,396,000 | 137,445,000 | 141,456,000 | 143,915,000 | 165,178,000 | 191,047,000 | 212,783,000 | 239,979,000 | 259,479,000 | 274,916,000 | 132,047,000 | 143,195,000 | 167,329,000 | 194,074,000 | 216,366,000 | 103,684,000 | 126,040,000 | 139,997,000 | 151,924,000 | 166,394,000 |
| liabilities and stockholders’ equity | ||||||||||||||||||||||||||||
| liabilities | ||||||||||||||||||||||||||||
| accounts payable | 7,571,000 | 4,627,000 | 6,662,000 | 7,878,000 | 10,190,000 | 6,728,000 | 6,060,000 | 7,610,000 | 7,252,000 | 8,843,000 | 14,175,000 | 13,723,000 | 11,291,000 | 14,661,000 | 13,552,000 | 11,024,000 | 6,803,000 | 6,543,000 | 9,372,000 | 10,320,000 | 9,825,000 | 10,260,000 | 7,628,000 | 8,911,000 | 5,907,000 | 5,872,000 | 6,827,000 | |
| accrued liabilities | 14,888,000 | 13,875,000 | 16,406,000 | 16,638,000 | 12,788,000 | 9,989,000 | 13,166,000 | 13,304,000 | 16,152,000 | 16,222,000 | 13,241,000 | 17,092,000 | 17,067,000 | 12,930,000 | 12,540,000 | 12,486,000 | 12,169,000 | 8,486,000 | 8,197,000 | 7,570,000 | 5,313,000 | 4,035,000 | 5,848,000 | 4,215,000 | 3,877,000 | 3,251,000 | 2,489,000 | |
| operating lease liabilities, current portion | 486,000 | 455,000 | 630,000 | 776,000 | 842,000 | 888,000 | 902,000 | 898,000 | 829,000 | 855,000 | 868,000 | 1,200,000 | 1,092,000 | 1,451,000 | 1,783,000 | 1,849,000 | 2,014,000 | 1,971,000 | 1,966,000 | 1,887,000 | 569,000 | 548,000 | 516,000 | 502,000 | 517,000 | |||
| total current liabilities | 22,945,000 | 18,957,000 | 23,698,000 | 25,292,000 | 43,470,000 | 17,605,000 | 20,128,000 | 21,812,000 | 24,233,000 | 25,920,000 | 28,284,000 | 32,015,000 | 29,450,000 | 29,042,000 | 27,875,000 | 25,359,000 | 20,986,000 | 17,000,000 | 19,535,000 | 19,777,000 | 15,707,000 | 14,843,000 | 13,992,000 | 13,628,000 | 10,301,000 | 9,123,000 | 9,316,000 | |
| accrued milestones | 3,200,000 | 3,200,000 | 3,200,000 | 2,000,000 | 2,250,000 | 2,250,000 | ||||||||||||||||||||||
| operating lease liabilities, long-term portion | 2,638,000 | 148,000 | 190,000 | 299,000 | 432,000 | 293,000 | 517,000 | 725,000 | 416,000 | 629,000 | 899,000 | 1,019,000 | 1,302,000 | 1,598,000 | 1,851,000 | 654,000 | 988,000 | 1,515,000 | 2,013,000 | 2,517,000 | 1,399,000 | 1,543,000 | 1,821,000 | 1,980,000 | 2,133,000 | |||
| other liabilities | 935,000 | 851,000 | 812,000 | 897,000 | 847,000 | 853,000 | 864,000 | 822,000 | 816,000 | 817,000 | 802,000 | 733,000 | 780,000 | 835,000 | 851,000 | 871,000 | 939,000 | 1,934,000 | 1,968,000 | 1,923,000 | 1,729,000 | 457,000 | 224,000 | |||||
| total liabilities | 29,718,000 | 23,156,000 | 27,900,000 | 28,488,000 | 48,699,000 | 24,126,000 | 26,884,000 | 28,734,000 | 27,715,000 | 29,616,000 | 32,235,000 | 36,017,000 | 33,782,000 | 33,575,000 | 32,677,000 | 29,134,000 | 25,163,000 | 22,699,000 | 26,211,000 | 26,683,000 | 21,321,000 | 18,744,000 | 17,463,000 | 17,745,000 | 17,658,000 | 14,484,000 | 11,397,000 | 11,366,000 |
| commitments and contingencies | ||||||||||||||||||||||||||||
| stockholders’ equity | ||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 5,500,000 shares authorized and none issued at june 30, 2025 and december 31, 2024 | ||||||||||||||||||||||||||||
| common stock | 5,000 | 5,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 4,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | |
| additional paid-in capital | 583,671,000 | 580,383,000 | 576,872,000 | 572,807,000 | 567,633,000 | 562,436,000 | 558,002,000 | 554,779,000 | 552,369,000 | |||||||||||||||||||
| accumulated other comprehensive income | -612,000 | 1,401,000 | 2,264,000 | -36,000 | 1,047,000 | 848,000 | 449,000 | 1,849,000 | 1,043,000 | 1,025,000 | 1,331,000 | 4,702,000 | 3,104,000 | 1,682,000 | 75,000 | 131,000 | 63,000 | -48,000 | ||||||||||
| accumulated deficit | -495,571,000 | -492,332,000 | -487,136,000 | -480,346,000 | -473,348,000 | -464,099,000 | -457,470,000 | -456,482,000 | -448,735,000 | -442,433,000 | -436,043,000 | -437,200,000 | -409,674,000 | -368,543,000 | -340,475,000 | -303,582,000 | -274,724,000 | -251,787,000 | -285,200,000 | -265,267,000 | -232,435,000 | -192,042,000 | -165,863,000 | -142,727,000 | -118,805,000 | -100,769,000 | -84,835,000 | -70,775,000 |
| total stockholders’ equity | 87,493,000 | 89,457,000 | 92,004,000 | 92,429,000 | 95,336,000 | 99,189,000 | 100,985,000 | 100,150,000 | 104,681,000 | 107,829,000 | 109,221,000 | 107,898,000 | 131,396,000 | 157,472,000 | 180,106,000 | 210,845,000 | 234,316,000 | 252,217,000 | 105,836,000 | 116,512,000 | 146,008,000 | 175,330,000 | 198,903,000 | 85,939,000 | 108,382,000 | 125,513,000 | 140,527,000 | 155,028,000 |
| total liabilities and stockholders’ equity | 117,211,000 | 112,613,000 | 119,904,000 | 120,917,000 | 144,035,000 | 123,315,000 | 127,869,000 | 128,884,000 | 132,396,000 | 137,445,000 | 141,456,000 | 143,915,000 | 165,178,000 | 191,047,000 | 212,783,000 | 239,979,000 | 259,479,000 | 274,916,000 | 132,047,000 | 143,195,000 | 167,329,000 | 194,074,000 | 103,684,000 | 126,040,000 | 139,997,000 | 151,924,000 | 166,394,000 | |
| preferred stock, 0.0001 par value, 5,500,000 shares authorized and none issued at march 31, 2025 and december 31, 2024 | ||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 5,500,000 shares authorized and none issued at december 31, 2024 and december 31, 2023 | ||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 5,500,000 shares authorized and none issued at september 30, 2024 and december 31, 2023 | ||||||||||||||||||||||||||||
| insurance recovery receivable related to legal settlement | 16,025,000 | |||||||||||||||||||||||||||
| accrued legal settlement | 19,650,000 | |||||||||||||||||||||||||||
| accrued milestone and royalty payments | 3,950,000 | 5,375,000 | 5,375,000 | 2,250,000 | 2,250,000 | 2,250,000 | 2,100,000 | 2,100,000 | 2,250,000 | 2,250,000 | 2,250,000 | 2,695,000 | 2,466,000 | 2,486,000 | 1,901,000 | 1,932,000 | 2,050,000 | 2,050,000 | 2,050,000 | 2,050,000 | ||||||||
| preferred stock, 0.0001 par value, 5,500,000 shares authorized and none issued at june 30, 2024 and december 31, 2023 | ||||||||||||||||||||||||||||
| | ||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 5,500,000 shares authorized and none issued at march 31, 2024 and december 31, 2023 | ||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 5,500,000 shares authorized and none issued at december 31, 2023 and december 31, 2022 | ||||||||||||||||||||||||||||
| accrued milestone payments | 5,375,000 | |||||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 5,500,000 shares authorized and none issued at september 30, 2023 and december 31, 2022 | ||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 5,500,000 shares authorized and none issued at june 30, 2023 and december 31, 2022 | ||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 5,500,000 shares authorized and none issued at march 31, 2023 and december 31, 2022 | ||||||||||||||||||||||||||||
| additional paid in capital | 549,233,000 | 543,929,000 | 540,392,000 | 537,962,000 | 524,329,000 | 519,206,000 | 514,198,000 | 509,049,000 | 504,091,000 | 391,558,000 | 381,803,000 | 378,455,000 | 367,293,000 | 228,532,000 | 227,187,000 | 226,216,000 | 225,352,000 | 225,848,000 | ||||||||||
| preferred stock, 0.0001 par value, 5,500,000 shares authorized and none issued at december 31, 2022 and december 31, 2021 | ||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 5,500,000 shares authorized and none issued at september 30, 2022 and december 31, 2021 | ||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 5,500,000 shares authorized and none issued at june 30, 2022 and december 31, 2021 | ||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 5,500,000 shares authorized and none issued at march 31, 2022 and december 31, 2021 | ||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 5,500,000 shares authorized and none issued at december 31, 2021 and december 31, 2020 | ||||||||||||||||||||||||||||
| accumulated other comprehensive income / | 1,371,000 | 225,000 | -526,000 | -28,000 | ||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 5,500,000 shares authorized at september 30, 2021 and december 31, 2020; none issued at september 30, 2021 and december 31, 2020 | ||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 5,500,000 shares authorized at june 30, 2021 and december 31, 2020; none issued at june 30, 2021 and december 31, 2020 | ||||||||||||||||||||||||||||
| accumulated other comprehensive loss | -13,000 | -91,000 | ||||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 5,500,000 shares authorized at march 31, 2021 and december 31, 2020; none issued at march 31, 2021 and december 31, 2020 | ||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 5,500,000 shares authorized at december 31, 2020 and december 31, 2019; none issued at december 31, 2020 and december 31, 2019 | ||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 5,500,000 shares authorized at september 30, 2020 and december 31, 2019; none issued at september 30, 2020 and december 31, 2019 | ||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 5,500,000 shares authorized at june 30, 2020 and december 31, 2019; none issued at june 30, 2020 and december 31, 2019 | ||||||||||||||||||||||||||||
| accumulated other comprehensive (loss)/income | -16,000 | |||||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 5,500,000 shares authorized at march 31, 2020 and december 31, 2019; none issued at march 31, 2020 and december 31, 2019 | ||||||||||||||||||||||||||||
| consolidated balance sheet data: | ||||||||||||||||||||||||||||
| working capital | 198,369,000 | |||||||||||||||||||||||||||
| restricted cash | 30,000 | 31,000 | 31,000 | |||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 5,500,000 shares authorized at september 30, 2019 and december 31, 2018; none issued at september 30, 2019 and december 31, 2018 | ||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 5,500,000 shares authorized at june 30, 2019 and december 31, 2018; none issued at june 30, 2019 and december 31, 2018 | ||||||||||||||||||||||||||||
| accumulated other comprehensive income/ | 7,000 | |||||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 5,500,000 shares authorized at march 31, 2019 and december 31, 2018; none issued at march 31, 2019 and december 31, 2018 | ||||||||||||||||||||||||||||
| deferred offering costs | ||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 5,500,000 shares authorized at december 31, 2018 and december 31, 2017; none issued at december 31, 2018 and december 31, 2017 | ||||||||||||||||||||||||||||
| preferred stock, 0.0001 par value, 5,500,000 shares authorized at september 30, 2018 and december 31, 2017; none issued at september 30, 2018 and december 31, 2017 |
We provide you with 20 years of balance sheets for Y-mAbs Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Y-mAbs Therapeutics. Explore the full financial landscape of Y-mAbs Therapeutics stock with our expertly curated balance sheets.
The information provided in this report about Y-mAbs Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.